Sequence: GWTLNSAGYLLGKINLKALAALAKKIL
PNA (peptide nucleic acid; antisense)
| Experiment Id | EXP001766 |
|---|---|
| Paper | Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in viv |
| Peptide | Transportan |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | 150 µM in 10 µL per injection (3 injections/36 h) |
| Rna Concentration | 150 µM in 10 µL per injection (3 injections/36 h) |
| Mixing Ratio | |
| Formulation Format | Covalent CPP–PNA conjugate (disulfide-linked) |
| Formulation Components | Carrier peptide (transportan or pAntp/penetratin) linked to cysteine-extended 21-mer PNA via disulfide bond; intracellular reduction releases PNA. |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | Rat (spinal cord dorsal horn; reflex facilitation model) |
| Administration Route | Intrathecal |
| Output Type | in vivo functional pain modulation |
| Output Value | Attenuated electrophysiologic effect consistent with reduced GalR1 function in vivo (reflex facilitation assay). |
| Output Units | |
| Output Notes | Intrathecal injections as above; compared to scrambled controls. PNA sequence: CCATTCCCTTCACTGAGGTTC (target rat GalR1 mRNA). |
| Toxicity Notes | |
| Curation Notes |